RhoVac’s prostate cancer vaccine phase 2 failure forces biotech to cut costsnews2022-05-30T10:52:39+00:00May 30th, 2022|FierceBiotech|
ASCO: Mirati cedes to Amgen’s Lumakras on durability in tight KRAS battlenews2022-05-27T13:05:08+00:00May 27th, 2022|FierceBiotech|
Addex’s eyelid data fail to make clear case for spasm expansionnews2022-05-27T11:43:12+00:00May 27th, 2022|FierceBiotech|
Iovance sinks 50% as pivotal cell therapy data disappoint investors, but approval plan pushes ahead anywaynews2022-05-27T08:57:27+00:00May 27th, 2022|FierceBiotech|
ASCO: Genentech touts bispecific data for DLBCL, calling it ‘groundbreaking’ for heavily pretreated patientsnews2022-05-27T00:20:55+00:00May 27th, 2022|FierceBiotech|
Chutes & Ladders—Alchemab CEO resigns immediately citing ‘personal reasons’news2022-05-26T20:22:01+00:00May 26th, 2022|FierceBiotech|
ASCO: Merck’s Keytruda combo data could spark hope for lymphoma patients who lack optionsnews2022-05-26T17:00:26+00:00May 26th, 2022|FierceBiotech|
Avadel’s shares crumble as narcolepsy drug delayed yet again, this time on patent issuenews2022-05-26T14:33:32+00:00May 26th, 2022|FierceBiotech|
Vertex scoops up Catalyst’s complement pipeline for $60M cashnews2022-05-26T13:47:56+00:00May 26th, 2022|FierceBiotech|
With the right partner, Pfizer gains fast-track tag for previously shelved NASH drugnews2022-05-26T12:12:33+00:00May 26th, 2022|FierceBiotech|
